BGMS — Bio Green Med Solution Share News
0.000.00%
Last trade - 00:00- $5.02m
- $1.68m
- $0.75m
Cyclacel jumps on promising data from early-stage cancer drug trail
Brief: Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results And Provides Business Update
Cyclacel Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Cyclacel Pharmaceuticals Inc expected to post a loss of 63 cents a share - Earnings Preview
Brief: Cyclacel Pharmaceuticals Achieves Key Business Objectives In First Half Of 2022 And Continues To Advance Clinical Pipeline
NASDAQ RESUMED AT 11:33 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:28 AM
NASDAQ RESUMED AT 09:46 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:40 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:39 AM
Brief: Cyclacel Pharmaceuticals Reports First Quarter 2022 Results
Cyclacel Pharmaceuticals Inc expected to post a loss of 68 cents a share - Earnings Preview
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:31 PM
Brief: Cyclacel Doses First Patient In Phase 1/2 Study Of Oral CYC140
NASDAQ RESUMED AT 03:45 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:41 PM
Cyclacel Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2021 Financial Results
Cyclacel Pharmaceuticals Inc expected to post a loss of 65 cents a share - Earnings Preview